Sandostatin Overdosage

A limited number of accidental overdoses of Sandostatin in adults and children have been reported. In adults, the doses ranged from 2,400-6,000 microgram/day administered by continuous infusion (100-250 microgram/hour) or subcutaneously (1,500 microgram t.i.d.). The adverse events reported were arrhythmia, hypotension, cardiac arrest, brain hypoxia, pancreatitis, hepatitis steatosis, diarrhea, weakness, lethargy, weight loss, hepatomegaly, and lactic acidosis. Atrioventricular blocks (including complete atrioventricular block) were reported in patients receiving higher doses of continuous infusion (100 microgram/hour) and/or bolus of Sandostatin intravenously (50 microgram bolus followed by 50 microgram/hour continuous infusion).
In children, the doses ranged from 50-3,000 microgram/day administered by continuous infusion (2.1-500 microgram/hour) or subcutaneously (50-100 microgram). The only adverse event reported was mild hyperglycemia.
No unexpected adverse events have been reported in cancer patients receiving Sandostatin at doses of 3,000-30,000 microgram/day in divided doses subcutaneously.
Treatment: The management of overdosage is symptomatic. Patients who received higher than recommended doses of intravenous octreotide are at increased risk of higher degree atrioventricular blocks and should be kept under appropriate cardiac monitoring.